FDA Grants Accelerated Approval to Zongertinib for Non-squamous NSCLC with HER2 Tyrosine Kinase Domain Activating Mutations By Ogkologos - August 29, 2025 514 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the Beamion LUNG-1 study Source RELATED ARTICLESMORE FROM AUTHOR Noninferiority of OS with 3 Months Compared to 6 Months of Adjuvant Chemotherapy for Patients with High-Risk Stage III Colorectal Cancer Patient Guide on Bone Health in Cancer Now Available Also in French Lung Cancer Death Rates Among Women in Europe Are Finally Levelling Off MOST POPULAR PSMA PET-CT Accurately Detects Prostate Cancer Spread, Trial Shows May 11, 2020 Grieving for Your Old Life After Cancer September 10, 2020 FDA Grants Accelerated Approval to Elranatamab-bcmm for Multiple Myeloma September 26, 2023 Sotorasib Shows Promising Activity and Acceptable Safety in Patients with Previously... January 10, 2023 Load more HOT NEWS A new target to slow down ageing and reduce blood cancer... Sacituzumab Govitecan Demonstrates Significant Improvement in Survival in Heavily Pretreated, Locally... Dad Sings “Ave Maria” For His Daughter At Disney World Breast Cancer Survivor Given 12 Months to Live After Left Side...
